Representative Publications
1. Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, Wei S, Grove S, Vatan L, Nelson R, Schaefer G, Allen S, Sankar K, Fecher L, Mendiratta-Lala M, Frankel T, Qin A, Waninger J, Tezel A, Alva A, Lao C, Ramnath N, Cieslik M, Harms P, Green M, Chinnaiyan A, Zou W. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell 2023 Feb 13;41(2):304-322.e7. doi:10.1016/j.ccell. 2022. 12.008. Epub 2023 Jan 12.
2. Li G, Kryczek I, Nam J, Li X, Li S, Li J, Wei S, Grove S, Vatan L, Zhou J, Du W, Lin H, Wang T, Subramanian C, Moon JJ, Cieslik M, Cohen M, Zou W. LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat Cell Biol. 2021 May;23(5):526-537. doi: 10.1038/s41556-021-00672-3. Epub 2021 May 6.
3. Li G, Wu X, Qian W, Cai H, Sun X, Zhang W, Tan S, Wu Z, Qian P, Ding K, Lu X, Zhang X, Yan H, Song H, Guang S, Wu Q, Lobie PE, Shan G, Zhu T. CCAR1 5' UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance. Cell Res. 2016 Jun;26(6):655-73. doi: 10.1038/cr.2016.32. Epub 2016 Mar 22.
4. Achinger-Kawecka J, Correa S, Hu J, Li G, Lindeboom RGH, Misale S, Monkkonen T, Nirmal AJ, Prekovic S, Sinha S, Trigos AS, Watson CJ. The 2023 generation. Nat Cancer. 2023 Dec;4(12):1630-1635. doi: 10.1038/s43018-023-00681-1.(co-corresponding author)
5. Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019 May;569(7755):270-274. doi: 10.1038/s41586-019-1170-y. Epub 2019 May 1.
6. Lin H, Kryczek I, Li S, Green MD, Ali A, Hamasha R, Wei S, Vatan L, Szeliga W, Grove S, Li X, Li J, Wang W, Yan Y, Choi JE, Li G, Bian Y, Xu Y, Zhou J, Yu J, Xia H, Wang W, Alva A, Chinnaiyan AM, Cieslik M, Zou W. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. Cancer Cell. 2021 Apr 12;39(4):480-493.e6. doi: 10.1016/j.ccell.2020.12.023. Epub 2021 Jan 28.
7. Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, Wei S, Zhao L, Vatan L, Wen B, Shu P, Sun D, Kleer C, Wicha M, Sabel M, Tao K, Wang G, Zou W. Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell Metab. 2018 Jul 3;28(1):87-103.e6. doi: 10.1016/j.cmet.2018.04.022. Epub 2018 May 24.
8. Du W, Hua F, Li X, Zhang J, Li S, Wang W, Zhou J, Wang W, Liao P, Yan Y, Li G, Wei S, Grove S, Vatan L, Zgodziński W, Majewski M, Wallner G, Chen H, Kryczek I, Fang JY, Zou W. Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation. Cancer Discov. 2021 Jul;11(7):1826-1843. doi: 10.1158/2159-8290.CD-20-1571. Epub 2021 Feb 24.
9. Zhou J, Kryczek I, Li S, Li X, Aguilar A, Wei S, Grove S, Vatan L, Yu J, Yan Y, Liao P, Lin H, Li J, Li G, Du W, Wang W, Lang X, Wang W, Wang S, Zou W. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. Nat Immunol. 2021 Apr;22(4):460-470. doi: 10.1038/s41590-021-00888-3. Epub 2021 Mar 25.
10. Li J, Wang W, Zhang Y, Cieślik M, Guo J, Tan M, Green MD, Wang W, Lin H, Li W, Wei S, Zhou J, Li G, Jing X, Vatan L, Zhao L, Bitler B, Zhang R, Cho KR, Dou Y, Kryczek I, Chan TA, Huntsman D, Chinnaiyan AM, Zou W. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J Clin Invest. 2020 May 1;130(5):2712-2726. doi: 10.1172/JCI134402.
11. Li S, Yu J, Huber A, Kryczek I, Wang Z, Jiang L, Li X, Du W, Li G, Wei S, Vatan L, Szeliga W, Chinnaiyan AM, Green MD, Cieslik M, Zou W. Metabolism drives macrophage heterogeneity in the tumor microenvironment Cell Rep. 2022 Apr 5;39(1):110609. doi: 10.1016/j.celrep.2022.110609.
12. Qian P, Zuo Z, Wu Z, Meng X, Li G, Wu Z, Zhang W, Tan S, Pandey V, Yao Y, Wang P, Zhao L, Wang J, Wu Q, Song E, Lobie PE, Yin Z, Zhu T. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res. 2011 Oct 15;71(20):6463-74. doi: 10.1158/0008-5472.CAN-11-1322. Epub 2011 Aug 25.
13. Zhang W, Wu M, Chong QY, Zhang M, Zhang X, Hu L, Zhong Y, Qian P, Kong X, Tan S, Li G, Ding K, Lobie PE, Zhu T. Loss of Estrogen-Regulated MIR135A1 at 3p21.1 Promotes Tamoxifen Resistance in Breast Cancer. Cancer Res. 2018 Sep 1;78(17):4915-4928. doi: 10.1158/0008-5472.CAN-18-0069. Epub 2018 Jun 26.
14. Tan S, Ding K, Li R, Zhang W, Li G, Kong X, Qian P, Lobie PE, Zhu T. Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2. Breast Cancer Res. 2014 Apr 15;16(2):R40. doi: 10.1186/bcr3644.
15. Tan S, Ding K, Chong QY, Zhao J, Liu Y, Shao Y, Zhang Y, Yu Q, Xiong Z, Zhang W, Zhang M, Li G, Li X, Kong X, Ahmad A, Wu Z, Wu Q, Zhao X, Lobie PE, Zhu T. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. J Biol Chem. 2017 Aug 18;292(33):13551-13564. doi: 10.1074/jbc.M117.780973. Epub 2017 Jun 21.
16. Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, Wu Z, Chen T, Wu W, Lobie PE, Zhu T. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One. 2012;7(8):e41523. doi: 10.1371/journal.pone.0041523. Epub 2012 Aug 2.
